Can a new eye drug cut injection frequency for AMD patients?

NCT ID NCT06271330

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 100 people with wet age-related macular degeneration (AMD) who have been getting regular eye injections with older drugs. They will switch to a newer drug called faricimab. The goal is to see if faricimab can extend the time between injections, meaning fewer trips to the doctor. The study will collect real-world data from medical records to compare injection intervals before and after the switch.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: faricimab
What this could lead to: If successful, this could show that faricimab allows patients with wet AMD to go longer between eye injections, reducing treatment burden.
What could go wrong: This is a small, observational study without a control group, so results may not prove faricimab is better. It also only looks at injection intervals, not vision outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Ducloyer
RECRUITING

Nantes, Nantes, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.